Summary
The provided statements do not match the supplied FDA prescribing information focus (dementia-related psychosis mortality warning). The label supports only the dementia-related psychosis risk/non-approval claims, but the majority of the listed statements are about pricing and are unsupported by the provided label content.
Category Scores
Accurate Statements
Elderly patients with dementia-related psychosis treated with SECUADO are at an increased risk of death, and SECUADO is not approved for dementia-related psychosis.
Supported by label sections 5.1 and 8.5 (increased risk of death; SECUADO not approved for dementia-related psychosis) and reinforced by 5.2 (cerebrovascular adverse reactions context; not approved for dementia-related psychosis).
Unsupported Statements
Secuado is a brand of rotigotine.
The supplied label content describes SECUADO as asenapine (transdermal system) and does not support rotigotine.
Secuado is a medicine used for Parkinson’s disease.
The supplied label content provided does not state Parkinson’s disease as an indication for SECUADO.
Pricing for Secuado can vary by country.
The supplied prescribing information does not contain pricing statements.
Pricing for Secuado can vary by pharmacy.
The supplied prescribing information does not contain pricing statements.
Pricing for Secuado can vary by insurance coverage.
The supplied prescribing information does not contain pricing statements.
Pricing for Secuado depends on dose strength.
The supplied prescribing information does not contain pricing statements.
Out-of-pocket cost for Secuado depends on where it is bought and what regimen is prescribed.
The supplied prescribing information does not contain pricing/out-of-pocket statements.
The biggest cost drivers for Secuado are country and local pricing/markups.
The supplied prescribing information does not contain pricing/cost-driver statements.
The biggest cost drivers for Secuado include prescribed strength and pack size.
The supplied prescribing information does not contain pricing/cost-driver statements.
The biggest cost drivers for Secuado include whether the patient has insurance, Medicare, or other coverage.
The supplied prescribing information does not contain coverage/cost-driver statements.
The biggest cost drivers for Secuado include pharmacy pricing differences.
The supplied prescribing information does not contain pricing/cost-driver statements.
The biggest cost drivers for Secuado include whether a generic or alternative is available in the market.
The supplied prescribing information does not contain generic/market availability cost statements.
Coverage and copays for Secuado depend on the plan and local formularies.
The supplied prescribing information does not contain coverage/copay statements.
In markets like the US, patients often reduce costs through insurance formulary tiers (preferred vs non-preferred).
The supplied prescribing information does not contain pricing strategy statements.
In markets like the US, patients often reduce costs through pharmacy discount programs.
The supplied prescribing information does not contain pricing strategy statements.
In markets like the US, patients often reduce costs through manufacturer savings offers (if available in their country).
The supplied prescribing information does not contain pricing strategy statements.
In markets like the US, patients may reduce costs by switching to an equivalent product if their clinician agrees.
The supplied prescribing information does not contain pricing advice/switching statements.
Secuado strength includes mg patch strength.
The supplied label excerpts include description/administration but do not provide the specific meaning of strength units for SECUADO.
Secuado cost estimation depends on the number of patches or the length of supply purchased.
The supplied prescribing information does not contain pricing/cost-estimation statements.
Contradictions
Low
AI Statement
Secuado is a brand of rotigotine.
Label Reference
Label description states: “SECUADO transdermal system contains asenapine, an atypical antipsychotic.” (Section 11 DESCRIPTION).
Important Omissions
The FDA label excerpts provided include an approved indication for SECUADO (treatment of adults with schizophrenia), but the response content does not address this indication.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only safety-relevant claim provided (increased mortality in elderly patients with dementia-related psychosis and non-approval for that use) matches the label. However, multiple unsupported non-label claims are present, including incorrect active ingredient (rotigotine) and an unsupported Parkinson’s disease use statement, which could mislead if taken as prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Large portion of the response consists of pricing/market access statements and other claims not present in the supplied FDA label excerpts; additionally, there is a contradiction about the active ingredient (rotigotine vs asenapine) and an unsupported indication (Parkinson’s disease).
Suggested Improvement
Limit statements to what is supported by the provided prescribing information. For safety labeling, keep the dementia-related psychosis increased mortality and non-approval language consistent with Sections 5.1/5.2/8.5, and ensure the correct active ingredient and labeled indication are used.